instability of polysorbates in protein biopharmaceutics · ddf summit dr. franziska edelmann and...
TRANSCRIPT
![Page 1: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/1.jpg)
DDF Summit
Dr. Franziska Edelmann and Dr. Kishore RavuriRoche Diagnostics GmbH
13th March 2019
Instability of Polysorbates in Protein Biopharmaceutics
![Page 2: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/2.jpg)
INTRODUCTION: POLYSORBATES
DEGRADATION MECHANISMS AND CONSEQUENCES
ANALYTICAL CONSIDERATIONS
MITIGATIONS
QUESTIONS & DISCUSSION
![Page 3: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/3.jpg)
IntroductionSurfactants In Commercial Protein Formulations
Source: List of licenced products, FDA.gov
![Page 4: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/4.jpg)
Structure of Polysorbate 20 and Polysorbate 80 (idealized)4
POE sorbitan
Hydrophilic “head”
Fatty acid
Hydrophobic “tail”
Ester bond
Structure of Polysorbate 20 Structure of Polysorbate 80
Ester bond
POE sorbitan
Hydrophilic “head”
Fatty acid
Hydrophobic “tail”
Double bond
The main difference between Polysorbate 20 and Polysorbate 80 lies in the esterified Fatty Acids/ Hydrophobic “Tail”
![Page 5: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/5.jpg)
• The Pharmacopoeias/ USP prescribe the distribution of fatty acid side chains:
5
• The solubility of the fatty acids decreases with increasing carbon chain length. In general, fatty acids with a carbon chain length ≥ C14 do show limited solubility in aqueous solutions (C14 – 1 µg/ml).
Carbon-Chain LengthNumber of Double
BondsPercentage
(%)
6 0 ≤1.0
8 0 ≤10.0
10 0 ≤10.0
12 0 40.0–60.0
14 0 14.0–25.0
16 0 7.0–15.0
18 0 ≤7.0
18 1 ≤11.0
18 2 ≤3.0
Polysorbate 20/ 80 are heterogeneous mixtures containing esterified fatty acids with reduced solubility
Carbon-Chain LengthNumber of Double
BondsPercentage
(%)
14 0 ≥5%
16 0 ≥16%
16 1 ≥8%
18 0 ≥6%
18 1 ≥58%
18 2 ≥18%
18 3 ≥4%
Polysorbate 20 Polysorbate 80
* In addition, there is presence of di- and tri-esters of POE sorbitan, as well as various impurities
Polysorbate 20/ 80 is a heterogeneous mixture
![Page 6: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/6.jpg)
INTRODUCTION: POLYSORBATES
DEGRADATION MECHANISMS AND CONSEQUENCES
ANALYTICAL CONSIDERATIONS
MITIGATIONS
QUESTIONS & DISCUSSION
![Page 7: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/7.jpg)
Polysorbate can degrade through two known mechanisms –Oxidation and Hydrolysis on the example of PS20
HydrolysisFatty Acids
Hydrolysis:
→ Enzymatic reaction
→ Degradation products: Only Fatty Acids (100%)
OxidationFatty acid EstersFatty acidsAldehydesKetonesAcidsPeroxidesAlkanes
etc.
Oxidation degradation products described in Kishore et al., 2011.
Oxidation:
→ Chemical reaction
→ Degradation products: mixture of
different products; 15% Fatty Acids
![Page 8: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/8.jpg)
• Polysorbate degradation leads to the formation of poorly soluble chemicals (e.g. fatty acids and fatty acid esters)
• Poorly soluble degradants accumulate and eventually precipitate out, forming particles
→ Particles are not desirable in parenteral products
→ Particle load may be sufficient to clog in-line filters used during drug infusion(has occurred for a placebo and resulted in product complaints)
→ In some cases, PS20 degradants can trigger protein aggregation
• In some instances, the PS20 degradation may be extensive enough that the protein is not protected anymore against interfacial stresses (1 case so far in Roche experience)
8
General problems associated with polysorbate degradation
![Page 9: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/9.jpg)
Oxidative Hydrolytic
Non linear kinetics (lag phase) Linear kinetics (zero order)
Relevant for placebos and actives. Not occurring in placebos. Chemical hydrolysis is negligible under such conditions (pH 5-7).
Chemical reaction Enzymatic reaction (in active samples, under relevant conditions)
Degradation products: fatty acid esters, peroxides, aldehydes, ketones, n-alkanes, fatty acids (~15%)
Degradation products: fatty acids (~100%).
Polysorbate degradation mechanisms (continued)
Polysorbate degradation can follow 2 mechanisms:
9
![Page 10: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/10.jpg)
Oxidative Hydrolytic
Non linear kinetics (lag phase) Linear kinetics (zero order)
Relevant for placebos and actives. Not occurring in placebos. Chemical hydrolysis is negligible under such conditions (pH 5-7).
Chemical reaction Enzymatic reaction (in active samples, under relevant conditions)
Degradation products: fatty acid esters, peroxides, aldehydes, ketones, n-alkanes, fatty acids (~15%)
Degradation products: fatty acids (~100%).
Polysorbate degradation mechanisms (continued)
Polysorbate degradation can follow 2 mechanisms:
10
![Page 11: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/11.jpg)
Identification of mechanism: Asking the right questions
• Is there oxidation-relevant degradation in DP?
• What does particle ID reveal?
• Do we see DP conc. dependent increase in degradation?
• What does the FFA content reveal?
![Page 12: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/12.jpg)
Method 1: Free Fatty Acids (FFA) stoichiometry
Measure PS at t0 and tn, measure FFA content for the same timepoints. If ~100% recovery of FFAs: degradation is hydrolytic. If ~15% recovery of FFAs (2-8°C) degradation is oxidative.
• Well suited for retrospective analysis of samples.
• A practical option for real-time stability.
• Most useful for quick troubleshooting on existing samples.
Method 2: Incubation with antioxidants
Incubate samples with and without antioxidants. Measure PS20 content. If antioxidants reduce the degradation rate, degradation has an oxidative component.
• Only prospective experiments are possible. Longer timeframe to get results.
• At 40°C oxidation is inevitable and results may be difficult to interpret.
• Well suited for studying hydrolytic degradation.
12
Determination of the PS degradation mechanism
![Page 13: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/13.jpg)
Method 1: Free Fatty Acids (FFA) stoichiometry
Measure PS at t0 and tn, measure FFA content for the same timepoints. If ~100% recovery of FFAs: degradation is hydrolytic. If ~15% recovery of FFAs (2-8°C) degradation is oxidative.
• Well suited for retrospective analysis of samples.
• A practical option for real-time stability.
• Most useful for quick troubleshooting on existing samples.
Method 2: Incubation with antioxidants
Incubate samples with and without antioxidants. Measure PS20 content. If antioxidants reduce the degradation rate, degradation has an oxidative component.
• Only prospective experiments are possible. Longer timeframe to get results.
• At 40°C oxidation is inevitable and results may be difficult to interpret.
• Well suited for studying hydrolytic degradation.
13
Determination of the PS degradation mechanism
![Page 14: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/14.jpg)
Enzymatic degradation
How do we detect degradation occurring due to HCPs from DS
1. Degradation depends on protein concentration
2. Degradation occurs in the presence of added antioxidants in the formulation
3. Can be inhibited by common lipase inhibitors
• Janssen: Enzyme-mediated hydrolysis of PS results in FFAs, in a lipid-specific manner as demonstrated by Labrenz from Janssen. (Labrenz et al. (2014) J Pharm Sci)
• Lilly, Haung et al. found that polysorbate 80 in drug product degraded enzymatically. (Huang et al., J Pharm Sci, 2016)
• PLBL2: Shire also found that an enzyme-mediated mechanism driven by trace amounts of HCPs was the cause of PS20 degradation. (Dixit et al., (2016) J Pharm Sci; 105,1657-66)
• LPL: Chiu et al. have demonstrated that a knockout for LPL helped reduce PS80 and PS20 degradation. (Chiu et al., (2016) Bitechnology and Bioengineering)
• Lysosomal LPLA2 as low as 0.3 ppm in 155 g/L mAb formulation. (T. Hall et al., (2016) J Pharm Sci 105, 1633-42)
• Both Lilly and Shire were not able to quantify and isolate a specific enzyme responsible for the observed PS20/80 degradation.
![Page 15: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/15.jpg)
Enzymatic degradation
How do we detect degradation occurring due to HCPs from DS
1. Degradation depends on protein concentration
2. Degradation occurs in the presence of added antioxidants in the formulation
3. Can be inhibited by common lipase inhibitors
• Janssen: Enzyme-mediated hydrolysis of PS results in FFAs, in a lipid-specific manner as demonstrated by Labrenz from Janssen. (Labrenz et al. (2014) J Pharm Sci)
• Lilly, Haung et al. found that polysorbate 80 in drug product degraded enzymatically. (Huang et al., J Pharm Sci, 2016)
• PLBL2: Shire also found that an enzyme-mediated mechanism driven by trace amounts of HCPs was the cause of PS20 degradation. (Dixit et al., (2016) J Pharm Sci; 105,1657-66)
• LPL: Chiu et al. have demonstrated that a knockout for LPL helped reduce PS80 and PS20 degradation. (Chiu et al., (2016) Bitechnology and Bioengineering)
• Lysosomal LPLA2 as low as 0.3 ppm in 155 g/L mAb formulation. (T. Hall et al., (2016) J Pharm Sci 105, 1633-42)
![Page 16: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/16.jpg)
INTRODUCTION: POLYSORBATES
DEGRADATION MECHANISMS AND CONSEQUENCES
ANALYTICAL CONSIDERATIONS
MITIGATIONS
QUESTIONS & DISCUSSION
![Page 17: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/17.jpg)
Analytical strategies for polysorbatesQuantification
• Fluorescence Micelle Assay (FMA)
• Relies on micelle forming ability of the surfactant
• Increase in fluorescence of NPN upon micelle formation
• Mixed-Mode HPLC with ELSD/CAD detection (MM-ELSD/CAD)
• Mixed-mode anion exchange or cation exchange column (eg Oasis MCX)
• PS20 detection using ELSD or CAD detector
• Also suitable for surfactants that do not form micelles, eg Poloxamer 188
![Page 18: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/18.jpg)
• Heterogeneity of PS20 can be further characterized using a shallow gradient RP-ELSD/CAD method (Hewitt et al. (2011) J Chromatogr A)
• Method is capable of resolving mono- from poly-ester species
non-esterified mono-esters poly-esters
Analytical strategies for polysorbatesCharacterization
![Page 19: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/19.jpg)
Analytical strategies for polysorbatesChoice of method is critical to monitor PS degradation
• Since FMA relies on micelle formation, its response is not uniform across the different PS20 ester species (Lippoldet al. 2017)
Not detectable w/neither FMA nor MM-ELSD/CAD
MM-ELSD/ CAD only
FMA and MM-ELSD/ CAD
POE sorbitan monolaurate
• Main component, POE sorbitan monolaureate, only detectable w/ MM-ELSD/CAD
![Page 20: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/20.jpg)
Analytical strategies for polysorbatesCase studies
Thermal 40°C (oxidative) Degradation
0 w
2 w
4 w
8 w
12 w
mono-esters poly-esters
• Polyesters are degraded more readily w/ temperature stress (Auto-Oxidation)
• FMA underestimates PS20 content since it cannot quantify monoester species
• Hydrolytic degradation is usually specific, i.e. either mono- or polyester are more readily degraded
• When monoesters are degraded, FMA overestimatestrue PS20 content
mono-esters poly-esters
Hydrolytic degradation (sample, control)
1M 5°C
3M 5°C
![Page 21: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/21.jpg)
• Degradation products from oxidative PS degradation can be detected using stir-bar-sorptive extraction coupled to GC-MS (Ravuri et al. 2011)
• Hydrolytic degradation results in formation of free fatty acids which can be detected by UPLC (following fluorescent labeling, Tomlinson et al. 2015) or by LC-MS
• Molar ratio of degraded PS20 and free fatty acids can give insight into major degradation pathway and confirm hydrolytic degradation
x mole of polysorbate x mole of FA formed
Hydrolytic degradation
Analytical strategies for polysorbatesCharacterization an Quantification of degradation products
![Page 22: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/22.jpg)
Considerations for Drug Product control strategyDriven by process and product knowledge
• PS20 should be monitored throughout the development lifecycle of a molecule, eg during formulation studies as well as during development stability studies
No change in PS content over product shelf life
• Leverage available data from development studies
• PS20 content not part of DP release or DP stability control strategy
• Monitoring only (eg as IPC)
Significant change in PS content but no impact on
Product CQAs
• Provide justification that PS is not a critical excipient (incl. assessment on impact of potential degradation products)
• PS20 content not specified for DP release and stability
Significant change in PS content and impact on
product CQAs
• Include PS content for DP release and stability
• Include appropriate justification for EoSL limit incl. potential impact of PS degradation products
![Page 23: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/23.jpg)
Considerations for Drug Product control strategyDriven by process and product knowledge
• PS20 should be monitored throughout the development lifecycle of a molecule, eg during formulation studies as well as during development stability studies
No change in PS content over product shelf life
• Leverage available data from development studies
• PS20 content not part of DP release or DP stability control strategy
• Monitoring only (eg as IPC)
Significant change in PS content but no impact on
Product CQAs
• Provide justification that PS is not a critical excipient (incl. assessment on impact of potential degradation products)
• PS20 content not specified for DP release and stability
Significant change in PS content and impact on
product CQAs
• Include PS content for DP release and stability
• Include appropriate justification for EoSL limit incl. potential impact of PS degradation products
![Page 24: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/24.jpg)
Considerations for Drug Product control strategyDriven by process and product knowledge
• PS20 should be monitored throughout the development lifecycle of a molecule, eg during formulation studies as well as during development stability studies
No change in PS content over product shelf life
• Leverage available data from development studies
• PS20 content not part of DP release or DP stability control strategy
• Monitoring only (eg as IPC)
Significant change in PS content but no impact on
Product CQAs
• Provide justification that PS is not a critical excipient (incl. assessment on impact of potential degradation products)
• PS20 content not specified for DP release and stability
Significant change in PS content and impact on
product CQAs
• Include PS content for DP release and stability
• Include appropriate justification for EoSL limit incl. potential impact of PS degradation products
![Page 25: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/25.jpg)
INTRODUCTION: POLYSORBATES
DEGRADATION MECHANISMS AND CONSEQUENCES
ANALYTICAL CONSIDERATIONS
MITIGATIONS
QUESTIONS & DISCUSSION
![Page 26: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/26.jpg)
Mitigations for oxidative polysorbate degradation
Handling of the raw material and buffers needs to be controlled
Potential critical processing steps:• Aliquoting of the raw material
• Storage
• Dilution in water / conditioning buffer and subsequent storage
Potential factors contributing to oxidative PS degradation:• Temperature
• Storage container
• Oxygen
• Light
• Metals
• Peroxides (VHP)26
![Page 27: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/27.jpg)
Hydrolytic degradation: chemical or enzymatic?
Evidence for a enzymatic degradation mechanism:
• Chemical hydrolysis rates cannot explain the PS20 degradation
• Degradation not mitigated by antioxidants
• Stoichiometric recovery of fatty acids, no presence of fatty acid esters or other oxidation markers
• Some effect of enzymes inhibitors
• Faster degradation in upstream pools
• Re-processing of the DP minimizes PS20 degradation
27
![Page 28: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/28.jpg)
Hydrolysis of polysorbates: potential mitigations
Ideally, the manufacturing process could control the polysorbate degradation to an acceptable level.
Different non-ionic surfactants can be used, albeit not universally.
If polysorbate degradation is unavoidable, different grades of polysorbate can be employed to reduce particle formation:
• Particle formation is thought to be caused by the most insoluble (e.g. longer chain) fatty acids
• Polysorbate grades only containing e.g. C12 or C18:1 esters will be less prone to particle formation
• For PS80: >98% oleate
Bedside filtration prior administration: recommended as an extra precaution
28
![Page 29: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/29.jpg)
THANK YOU
![Page 30: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/30.jpg)
APPENDIX
![Page 31: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/31.jpg)
• Occurs in the presence of free radicals and peroxides
• Leads to a mixture of different products, preferentially higher order esters; only 15% fatty acids
• Occurs most likely in placebo, but can also occur in active
• Oxidative PS80 degradation does not lead to particle formation but PS20 often does
• Antioxidants like methionine can mitigate oxidative degradation of PS20 but not of PS80
• Has a strong temperature dependency
• Radicals can be induced during long-term storage and handling of the raw material and diluted stock solutions by exposure to light and oxygen
• Can be minimized through changes in handling practices (raw material, buffer solutions)
31
What we know about Polysorbate Oxidative Degradation
Example of impact of oxidative degradation of Polysorbate 20Lam et. al. Pharm Res. 2011 Oct;28(10):2543-55. doi: 10.1007/s11095-011-0482-x. Epub 2011 Jun 8.
![Page 32: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/32.jpg)
• Occurs at the ester bond and thus fatty acids are the primary degradation product
• Fatty acids, especially higher homologues, are know to have low solubility can precipitate out of solution as visible particles when the concentration is beyond the limit of solubility
• Chemical hydrolysis rates are negligible under relevant conditions
➔ As described in literature, presence of certain impurities can catalyze the reaction and increase the rate of hydrolysis yielding higher concentration of fatty acids which precipitate and lead to visible particle formation
➔ Trace amounts of such a catalyst seems to be sufficient
➔Detection of catalyst is very challenging
32
What we know about Polysorbate Hydrolytic Degradation
Hydrolytic degradation in active solutions is hypothesized to be due to a catalyst e.g. trace levels of lipase- or esterase-like enzyme(s), bioburden, others? But hypothesis need to be proven
![Page 33: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/33.jpg)
Doing now what patients need next
![Page 34: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/34.jpg)
A shallow gradient ELSD method gives insight into the distribution of fatty acid esters.
6.3 8.0 9.0 10.0 11.0 12.0 13.0 14.0 15.0 16.0 17.0 18.0 19.0 20.1-137
0
200
400
600
918
2013-09-18 0.04% AND 0.02% PS20 1 and 5 mM AAPH CAPA STUDY #20 [modified by doshin1] ELSD_1
mV
min
1 -
C8
este
r -
7.64
3
2 -
C8
IPE
- 7
.997
3 -
C10
est
er -
8.9
03
4 -
C12
est
er -
9.8
50
5 -
C14
est
er -
10.
303
6 -
C16
est
er -
11.
270
7 -
C18
:1 e
ster
- 1
2.02
7
8 -
C12
die
ster
- 1
3.15
7
9 -
C12
C14
C16
C18
di-t
ri es
ter
- 13
.747
1 - New Peak
2 - C8 ester
3 - C8 IPE
4 - C10 ester
5 - C12 ester
6 - C14 ester
7 - C16 ester
8 - C18:1 ester
9 - C12 diester
10 - C12C14C16C18 di-tri ester
Dan Hewitt et al., J. Chromatogr. A 1218 (2011) 2138-2145
Characterization of Polysorbate 20: Distribution of POE sorbitan esters
![Page 35: Instability of Polysorbates in Protein Biopharmaceutics · DDF Summit Dr. Franziska Edelmann and Dr. Kishore Ravuri Roche Diagnostics GmbH 13th March 2019 Instability of Polysorbates](https://reader033.vdocuments.mx/reader033/viewer/2022042116/5e937ca3c5193636092ade77/html5/thumbnails/35.jpg)
Doing now what patients need next